Announcement PDF ASX ANNOUNCEMENT 27 February 2025 Expiry of listed CYPOA Options Melbourne, Australia; 27 February 2025: Cynata Therapeutics Limited (ASX: CYP, “Cynata” or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, advises that the 18,104,720 listed options trading under the code CYPOA (Options) will expire, unless exercised on or before 1 April 2025. Each Option is exercisable at a price of $0.30 (30 cents), and entitles the holder to subscribe for one fully paid ordinary share of the Company. The Options were issued on 1 June 2023 under a prospectus dated 19 April 2023. Enclosed is the letter sent to each Option holder today. -ENDSAuthorised for release by the Company Secretary of Cynata Therapeutics Limited CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com Peter Webse, Company Secretary, +61 (0)409 328 199, pwebse@governancecorp.com.au About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors. Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK, in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD), and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP001 in patients undergoing kidney transplant; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome. Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com 27 February 2025 Dear Option Holder Important Notice – Expiry of Listed CYPOA Options Cynata Therapeutics Limited (ASX: CYP, “Cynata” or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, notifies holders of the 18,104,720 outstanding listed options (ASX Code: CYPOA) (Options) that the Options will expire on 1 April 2025. The Company provides the following information to Option holders. 1. This Notice applies to 18,104,720 outstanding listed options (ASX Code: CYPOA) exercisable on or before 1 April 2025. 2. Each Option is exercisable to acquire one fully paid ordinary share (Share) in the Company at an exercise price of $0.30. Accordingly, if all of the Options were exercised, a total of [insert] Shares would be issued. 3. The due date for payment to exercise the Options is 5.00 pm (AEST) on 1 April 2025. 4. If you (as the Option holder) do not elect to exercise your Options by 5.00 pm (AEST) on 1 April 2025, your Options will lapse and all rights under the Options will cease. 5. Quotation of the Options will cease at close of trading on Wednesday, 26 March 2025, being 4 business days before 1 April 2025. 6. The last market sale price on ASX on 24 February 2025 of the Shares, into which the Options are exercisable, was $0.24. 7. The highest and lowest market sale price of the Shares on ASX during the past 3 months was a high of $0.27 on 7 February 2025 and a low of $0.17 on 16 December 2024. 8. No underwriting agreement exists in respect of the Options. To exercise some or all of your Options, complete the Notice of Exercise of Options form available from the Company’s share registry, Automic Pty Ltd (details below), sign it and send it to Automic using the instructions provided on the form. You will be required to pay the exercise price of the Options via electronic funds transfer (details are provided on the Notice of Exercise of Options). Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com Automic Group, PO Box 5193, Sydney NSW 2001 Tel: 1300 288 664 (within Australia) or +61 2 9698 5414 (international) Email: hello@automic.com.au Your completed Notice of Exercise of Options form, together with payment in cleared funds, must be received by the Company by 5.00pm on Tuesday, 1 April 2025, failing which your Options will lapse. If you have any queries regarding your Options or how to exercise them, please contact the Company Secretary on +61 409 328 199 or pwebse@governancecorp.com.au. Yours sincerely Peter Webse Company Secretary Cynata Therapeutics Limited About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors. Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. A Phase 2 clinical trial in GvHD under a cleared US FDA IND, as well as trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing, while a trial in renal transplant is expected to commence in the near future. In addition, Cynata has also demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome. Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com